Le disease in peripheral blood or bone marrow even when extremely sensitive immunophenotypic or molecular solutions are made use of to appear for residual illness. These sufferers are viewed as to have achieved a minimal residual disease (MRD) negative status.17-20 Many phase II trials have demonstrated that sufferers attaining MRD negativity have a signif-icantly longer survival than those who re